Omeros Corporation (OMER)
Health Care ยท Pharmaceutical Preparations
Omeros Corporation (OMER) is listed on Nasdaq, where its shares have traded since October 8, 2009. SentiSense covers Omeros Corporation in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Gregory A. Demopulos is its chief executive officer. The company reports 175 employees, and its corporate website is www.omeros.com.
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Latest reported results
Omeros Corporation reported revenue of $28.5 million for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 165 institutions reported holding OMER, with 35.9 million shares worth $341.9 million in aggregate. The largest reported holders were BlackRock, Vanguard and Ingalls & Snyder. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on OMER
- OMER sentiment: whether news and social coverage of Omeros Corporation leans bullish or bearish, and the stories driving it.
- OMER ownership: all 165 reporting institutions, plus insider and congressional trades.
- OMER financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Omeros Corporation: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Omeros Corporation do?
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
What sector is OMER in?
SentiSense classifies Omeros Corporation in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does OMER stock trade?
Omeros Corporation (OMER) is listed on Nasdaq, where its shares have traded since October 8, 2009.
Who is the CEO of Omeros Corporation?
Gregory A. Demopulos is the chief executive officer of Omeros Corporation.